生物制剂时代炎症性肠病的外科治疗  

Surgery for inflammatory bowel disease in the era of biologics

作　　者：刘威[1] 周伟[1] Wei Liu;Wei Zhou(Department of General Surgery,IBD Center,Sir Run Run Shaw Hospital,School of Medicine,Zhejiang University,Hangzhou 310016,Zhejiang Province,China)

机构地区：[1]浙江大学医学院附属邵逸夫医院普外科/炎症性肠病中心,浙江省杭州市310016

出　　处：《世界华人消化杂志》2021年第22期1311-1315,共5页World Chinese Journal of Digestology

摘　　要：随着生物制剂的广泛应用,炎症性肠病(inflammatory bowel diseases,IBD)的治疗发生了巨大的变化.外科手术在治疗中仍然起到了必不可少的作用.且随着越来越多的患者接受生物制剂治疗,外科手术也需适应生物制剂时代对疾病产生的影响.本文旨在综述生物制剂时代外科治疗在IBD治疗中的作用,以及这些药物对围手术期的影响.Therapy for inflammatory bowel diseases(IBD)has changed dramatically in recent years with the wide use of biologics.Despite these advances in medical therapy,surgery still plays an indispensable role in the management of IBD.And with more and more patients receiving biologics,surgeons also need to adapt to the impact of biologics on the disease.The purpose of this article is to review the role of surgery in the treatment of IBD in the era of biologics and the impact of these medications on perioperative outcomes.

关 键 词：炎症性肠病 生物制剂 手术 

分 类 号：R656[医药卫生—外科学]